Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6463162 | 1.00 | TDP1 (0.33) | TDP1PGD | |
| SCHEMBL9237983 | 0.80 | TDP1 (0.30) | TDP1 | |
| SCHEMBL9230880 | 0.80 | TDP1 (0.30) | TDP1 | |
| SCHEMBL29666105 | 0.77 | TSHR (0.37) | — | |
| SCHEMBL27712299 | 0.77 | TSHR (0.37) | — | |
| SCHEMBL6465964 | 0.69 | — | — | |
| SCHEMBL7580650 | 0.67 | TRPV1 (0.30) | TDP1PGD | |
| SCHEMBL7574851 | 0.67 | TRPV1 (0.30) | TDP1PGD | |
| SCHEMBL7573055 | 0.67 | TRPV1 (0.30) | TDP1PGD | |
| SCHEMBL7579997 | 0.67 | TRPV1 (0.30) | TDP1PGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004044-A1 | Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en-22-one 16-0-(2-0-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1->3)-(2-0-acetyl-alpha-L-arabinopyranoside)] or OSW-1 and its derivatives for cancer therapeutics | BOARD OF REGENTS | 2005-01-06 | — | — | US | disclosed |
| US-6753414-B2 | PREPARING NATURALLY OCCURRING SAPONINS SUCH AS OSW-L | UNIVERSITY OF IOWA RESEARCH FOUNDATION, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030069214-A1 | Process for preparing saponin compounds | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069214-A1 | Process for preparing saponin compounds | LSS, CYP51A1, CYP4F11 | TDP1 2989/4885PGD 1309/4885 |
| US-20050004044-A1 | Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en-22-one 16-0-(2-0-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1->3)-(2-0-acetyl-alpha-L-arabinopyranoside)] or OSW-1 and its derivatives for cancer therapeutics | OSBP2, OSBP, OSBPL3 | TDP1 3331/4885PGD 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.